全文获取类型
收费全文 | 49797篇 |
免费 | 3122篇 |
国内免费 | 155篇 |
专业分类
耳鼻咽喉 | 653篇 |
儿科学 | 1423篇 |
妇产科学 | 856篇 |
基础医学 | 5904篇 |
口腔科学 | 811篇 |
临床医学 | 5057篇 |
内科学 | 10705篇 |
皮肤病学 | 860篇 |
神经病学 | 4634篇 |
特种医学 | 1999篇 |
外国民族医学 | 1篇 |
外科学 | 8712篇 |
综合类 | 477篇 |
一般理论 | 48篇 |
预防医学 | 3153篇 |
眼科学 | 808篇 |
药学 | 3046篇 |
中国医学 | 45篇 |
肿瘤学 | 3882篇 |
出版年
2023年 | 247篇 |
2022年 | 418篇 |
2021年 | 1084篇 |
2020年 | 625篇 |
2019年 | 1100篇 |
2018年 | 1306篇 |
2017年 | 955篇 |
2016年 | 990篇 |
2015年 | 1172篇 |
2014年 | 1822篇 |
2013年 | 2321篇 |
2012年 | 3747篇 |
2011年 | 3898篇 |
2010年 | 2181篇 |
2009年 | 1863篇 |
2008年 | 3408篇 |
2007年 | 3583篇 |
2006年 | 3564篇 |
2005年 | 3467篇 |
2004年 | 3336篇 |
2003年 | 3102篇 |
2002年 | 2848篇 |
2001年 | 379篇 |
2000年 | 270篇 |
1999年 | 398篇 |
1998年 | 570篇 |
1997年 | 457篇 |
1996年 | 351篇 |
1995年 | 348篇 |
1994年 | 328篇 |
1993年 | 268篇 |
1992年 | 210篇 |
1991年 | 197篇 |
1990年 | 174篇 |
1989年 | 160篇 |
1988年 | 161篇 |
1987年 | 146篇 |
1986年 | 142篇 |
1985年 | 143篇 |
1984年 | 181篇 |
1983年 | 180篇 |
1982年 | 203篇 |
1981年 | 177篇 |
1980年 | 124篇 |
1979年 | 83篇 |
1978年 | 78篇 |
1977年 | 69篇 |
1976年 | 45篇 |
1975年 | 30篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
994.
Developments during the past few years have resulted in multiple kinds of platelet products for transfusion. This involves different collection methods, containers, preservative solutions, modifications of storage temperatures and durations, and additional treatments such as pathogen reduction. Much experience has been obtained testing these processes in vitro to seek indications of in vivo effectiveness. Availability of an in vitro method that correlated with in vivo effectiveness would be extremely valuable for these different kinds of platelet products and as more innovation in platelet preparation occurs in the future. This report reviews the methods for in vitro platelet testing with a view to their in vivo implications and whether such testing could be helpful in projecting the clinical effectiveness of different platelet products. 相似文献
995.
996.
997.
998.
999.
1000.
Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline 总被引:2,自引:0,他引:2
Martin KA Chang RJ Ehrmann DA Ibanez L Lobo RA Rosenfield RL Shapiro J Montori VM Swiglo BA 《The Journal of clinical endocrinology and metabolism》2008,93(4):1105-1120
OBJECTIVE: Our objective was to develop clinical practice guidelines for the evaluation and treatment of hirsutism in premenopausal women. PARTICIPANTS: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, two methodologists, and a medical writer. The Task Force received no corporate funding or remuneration. EVIDENCE: Systematic reviews of available evidence were used to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria to describe both the quality of evidence and the strength of recommendations. We used "recommend" for strong recommendations, and "suggest" for weak recommendations. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the Task Force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Core Committee (CACC), and Council. The version approved by the CGS and CACC was placed on The Endocrine Society's Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. CONCLUSIONS: We suggest testing for elevated androgen levels in women with moderate or severe hirsutism or hirsutism of any degree when it is sudden in onset, rapidly progressive, or associated with other abnormalities such as menstrual dysfunction, obesity, or clitoromegaly. For women with patient-important hirsutism despite cosmetic measures, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For women who choose hair removal therapy, we suggest laser/photoepilation. 相似文献